Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesLoans and Notes ReceivablesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - Other
Ratios

Gyre Therapeutics (GYRE) Loans and Notes Receivables (2022 - 2025)

Gyre Therapeutics (GYRE) has disclosed Loans and Notes Receivables for 4 consecutive years, with $693000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Loans and Notes Receivables rose 661.54% to $693000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $693000.0, a 661.54% increase, with the full-year FY2024 number at $4.4 million, up 1024.16% from a year prior.
  • Loans and Notes Receivables was $693000.0 for Q3 2025 at Gyre Therapeutics, up from $499000.0 in the prior quarter.
  • In the past five years, Loans and Notes Receivables ranged from a high of $4.4 million in Q4 2024 to a low of $91000.0 in Q3 2024.
  • A 4-year average of $1.4 million and a median of $693000.0 in 2025 define the central range for Loans and Notes Receivables.
  • Peak YoY movement for Loans and Notes Receivables: crashed 74.44% in 2023, then skyrocketed 1024.16% in 2024.
  • Gyre Therapeutics' Loans and Notes Receivables stood at $1.5 million in 2022, then plummeted by 74.44% to $389000.0 in 2023, then surged by 1024.16% to $4.4 million in 2024, then plummeted by 84.15% to $693000.0 in 2025.
  • Per Business Quant, the three most recent readings for GYRE's Loans and Notes Receivables are $693000.0 (Q3 2025), $499000.0 (Q2 2025), and $2.1 million (Q1 2025).